{Reference Type}: Journal Article
{Title}: The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.
{Author}: García-Sanz R;Tedeschi A;
{Journal}: Hematol Oncol Clin North Am
{Volume}: 37
{Issue}: 4
{Year}: 2023 Aug 26
{Factor}: 2.861
{DOI}: 10.1016/j.hoc.2023.04.006
{Abstract}: Waldenström's macroglobulinemia (WM) is an immunoglobulin M monoclonal gammopathy produced by a bone marrow lymphoplasmacytic lymphoma, an indolent non-Hodgkin lymphoma in which the cure is still an unmet challenge. Combinations with alkylating agents, purine analogs, and monoclonal antibodies, Bruton tyrosine kinase, and proteasome inhibitors are used for the treatment of relapsed and refractory patients. Moreover, new additional agents can be seen on the horizon as potential effective therapies. No consensus on a preferred treatment in the relapsed setting is available yet.